Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines., PMID:40391211
Aberrant Lower CD6 Expression on Peripheral B Cells Associated With Liver/Kidney Injury and Autoantibody Production of Systemic Lupus Erythematosus Patients., PMID:40134233
CD6 regulates CD4 T follicular helper cell differentiation and humoral immunity during murine coronavirus infection., PMID:39679790
Evaluation of inflammatory biomarkers and their association with anti-SARS-CoV-2 antibody titers in healthcare workers vaccinated with BNT162B2., PMID:39247198
CD6 Regulates CD4 T Follicular Helper Cell Differentiation and Humoral Immunity During Murine Coronavirus Infection., PMID:39091786
Expression of CD6 in Aggressive NK/T-cell Neoplasms and Assessment as a Potential Therapeutic Target: A Bone Marrow Pathology Group Study., PMID:39089930
Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program., PMID:38759368
Recombinant CD5 and CD6 Ectodomains Induce Antiparasitic and Immunomodulatory Effects in Secondary Cystic Echinococcosis., PMID:38625016
Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells., PMID:38280067
CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies., PMID:38139340
A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders., PMID:37917882
Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells., PMID:37886483
Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis., PMID:37691918
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma., PMID:37573404
Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery., PMID:37514028
Paraneoplastic or not? Sirtuin 2 in anti-N-methyl-d-aspartate receptor encephalitis., PMID:37483157
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT., PMID:37073744
Investigating combination benefit of PD1 and LAG3 co-blockade using an engineered cellular bioassay., PMID:37044037
Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis., PMID:36865872
Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia., PMID:36451826
Keratinocyte-induced costimulation of human T cells through CD6 - but not CD2 - activates mTOR and prevents oxidative stress., PMID:36353616
CD6 deficiency impairs early immune response to bacterial sepsis., PMID:36157587
COVID-19 mortality and its predictors in the elderly: A systematic review., PMID:35620541
Th1 and Th17 cells are resistant towards T cell activation-induced downregulation of CD6., PMID:35487454
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation., PMID:35484649
Gene Variation at Immunomodulatory and Cell Adhesion Molecules Loci Impacts Primary Sjögren's Syndrome., PMID:35372412
The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses., PMID:34981775
Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center., PMID:34045817
Promise and complexity of lupus mouse models., PMID:33972783
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19., PMID:33835886
CD6 is a target for cancer immunotherapy., PMID:33497367
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases., PMID:33397150
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab., PMID:33304584
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients., PMID:33292350
Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19., PMID:33105142
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?, PMID:33048300
Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era., PMID:33015549
SOSTDC1 promotes invasion and liver metastasis in colorectal cancer via interaction with ALCAM/CD166., PMID:32801337
Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications., PMID:32700604
Anti-CD6 mAbs for the treatment of psoriasis., PMID:32466689
A New Hope for CD56negCD16pos NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases., PMID:32373555
Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6., PMID:32307907
Modulation of CD4 T cell function via CD6-targeting., PMID:31481324
Using monoclonal antibodies to investigate molecular immunology: there's more to know!, PMID:31291693
Domain-specific CD6 monoclonal antibodies identify CD6 isoforms generated by alternative-splicing., PMID:31162836
Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India., PMID:31119094
New Targeted Therapies for Uncontrolled Asthma., PMID:31076057
A sequence conserved between CD5 and CD6 binds an FERM domain and exerts a restraint on T-cell activation., PMID:30460991
Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells., PMID:30356797
CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action., PMID:29772075
For research use only. Not for human or drug use.
